AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Humana Extends TailorCare Tie-Up to Enhance MA Member Health
HUM expands its TailorCare partnership to Dallas and Denver, aiming to boost MA member health and cut MSK-related costs.
Is ANI ( ANIP ) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Is Clover Health Investments ( CLOV ) Outperforming Other Medical Stocks This Year?
Here is how Clover Health Investments, Corp. (CLOV) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector ...
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
INCY Announces New Late-Stage Data on Skin Disease Drug
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
Puma Biotechnology shares rise nearly 30% in three months on rising Nerlynx sales, with key data on pipeline drug alisertib due later this year.
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
3 Reasons Why Growth Investors Shouldn't Overlook ANI ( ANIP )
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Is Adagene ( ADAG ) Stock Outpacing Its Medical Peers This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
ANI Pharmaceuticals, Inc. ( ANIP ) Hit a 52 Week High, Can the Run Continue?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
Adaptive Biotechnologies Corporation ( ADPT ) Hits Fresh High: Is There Still Room to Run?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI Pharmaceuticals ( ANIP ) is a Great Momentum Stock: Should You Buy?
Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.
IOVA Stock Drops 6% on $350M Common Stock Offering
Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
PRINCETON, N.J., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ( Nasdaq: ANIP ) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team will present at two upcoming ...
Is ANI ( ANIP ) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
Is Amarin ( AMRN ) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
ANI Pharmaceuticals, Inc. ( ANIP ) Hits Fresh High: Is There Still Room to Run?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cg Oncology ( CGON ) Q2 Loss Widens 93%
Cg Oncology ( NASDAQ:CGON ) , a clinical-stage biotechnology company focused on developing therapies for bladder cancer, reported its second quarter fiscal 2025 earnings on August 8, 2025. The company disclosed a net loss that was more than double that of the same quarter in 2024.
ANI Pharmaceuticals ( ANIP ) Q2 Earnings and Revenues Surpass Estimates
ANI (ANIP) delivered earnings and revenue surprises of +30.43% and +12.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting -
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( Nasdaq: ANIP ) ( ANI or the Company ) today announced financial results and business highlights for the second quarter ended June 30, 2025.
Sutro Biopharma, Inc. ( STRO ) Reports Q2 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of +64.10% and +293.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ( NASDAQ: ANIP ) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ANIP today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Kymera Therapeutics, Inc. ( KYMR ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals ( ANIP ) Earnings Expected to Grow: What to Know Ahead of Q2 Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kiniksa Pharmaceuticals International, plc ( KNSA ) Tops Q2 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +27.78% and +7.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema ( DME ) - ANI Pharmaceuticals ( NASDAQ:ANIP )
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A.
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema ( DME )
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm ...
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Will ANI ( ANIP ) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
PRINCETON, N.J., July 02, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ( Nasdaq: ANIP ) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, ...
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th - ANI Pharmaceuticals ( NASDAQ:ANIP )
PRINCETON, N.J., July 02, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ANIP today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, ...
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology ( EULAR ) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster ...
ANI Pharmaceuticals Announces Presentation of New Preclinical Data - ANI Pharmaceuticals ( NASDAQ:ANIP )
PRINCETON, N.J., June 12, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ANIP today announced new preclinical data on the use of Purified Cortrophin Gel ( repository corticotropin injection USP ) ( Cortrophin Gel ) in a mouse model of murine collagen-induced ...
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
PRINCETON, N.J., May 27, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ( Nasdaq: ANIP ) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows: ...
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - ANI Pharmaceuticals ( NASDAQ:ANIP )
PRINCETON, N.J., May 27, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ANIP today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Agilon Health ( NYSE:AGL ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares ...
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ( Nasdaq: ANIP ) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C.
